Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 13/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659535 | 0.91 | ALDH1A1 (0.61) | NAMPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5656620 | 0.89 | LMNA (0.61) | NAMPTALDH1A1 | |
| SCHEMBL5655917 | 0.89 | NAMPT (0.59) | NAMPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5660187 | 0.86 | ALDH1A1 (0.52) | NAMPTALDH1A1 | |
| SCHEMBL5658814 | 0.86 | ADRA2A (0.59) | NAMPTSMN1; SMN2 | |
| SCHEMBL5666757 | 0.85 | EPHX2 (0.55) | — | |
| SCHEMBL5654940 | 0.84 | ALDH1A1 (0.58) | NAMPTALDH1A1 | |
| SCHEMBL5658337 | 0.83 | ADRA2A (0.55) | NAMPTSMN1; SMN2 | |
| SCHEMBL5657361 | 0.83 | ADRA2A (0.55) | SMN1; SMN2 | |
| SCHEMBL5658534 | 0.82 | ADRA2A (0.50) | NAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-6998414-B2 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-02-14 | — | — | US | disclosed |
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | INSR, INSRR, GIPR | NAMPT 1589/4885ALDH1A1 2894/4885SMN1; SMN2 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.